Sterling Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Sterling Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.01K	Sell	376 -245	-39%	-$3.56K	﹤0.01%	2427
2026 Q1	$7.41K	Buy	621 +40	+7%	+$448	﹤0.01%	2534
2025 Q4	$7.27K	Buy	581 +369	+174%	+$4.26K	﹤0.01%	2761
2025 Q3	$1.94K	Buy	212 +29	+16%	+$217	﹤0.01%	2984
2025 Q2	$1K	Sell	183 -371	-67%	-$2.31K	﹤0.01%	3063
2025 Q1	$3.48K	Sell	554 -255	-32%	-$1.22K	﹤0.01%	2338
2024 Q4	$3.33K	Buy	809 +700	+642%	+$2.24K	﹤0.01%	2618
2024 Q3	$364	Buy	+109	New	+$324	﹤0.01%	2982

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Sterling Capital Management's TRVI Position: Q2 2026 in Review

Sterling Capital Management reduced its Trevi Therapeutics (TRVI) stake by 39% in Q2 2026, selling an estimated $3.56K and leaving 376 shares worth $7.01K. The position accounts for ﹤0.01% of the portfolio, ranked #2427.

Sterling Capital Management first reported a position in TRVI in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.41K in Q1 2026. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Sterling Capital Management held 376 shares of Trevi Therapeutics worth $7.01K as of Q2 2026.
Sterling Capital Management sold 245 Trevi Therapeutics shares in Q2 2026, an estimated $3.56K.
Trevi Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2427 holding.
Sterling Capital Management first reported a position in Trevi Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Trevi Therapeutics position peaked at $7.41K in Q1 2026.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.